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Abstract: Coenzyme Q10 (CoQ10) is classically viewed as an important endogenous antioxidant and
key component of the mitochondrial respiratory chain. For this second function, CoQ molecules
seem to be dynamically segmented in a pool attached and engulfed by the super-complexes I + III,
and a free pool available for complex II or any other mitochondrial enzyme that uses CoQ as a cofactor.
This CoQ-free pool is, therefore, used by enzymes that link the mitochondrial respiratory chain to
other pathways, such as the pyrimidine de novo biosynthesis, fatty acid β-oxidation and amino acid
catabolism, glycine metabolism, proline, glyoxylate and arginine metabolism, and sulfide oxidation
metabolism. Some of these mitochondrial pathways are also connected to metabolic pathways
in other compartments of the cell and, consequently, CoQ could indirectly modulate metabolic
pathways located outside the mitochondria. Thus, we review the most relevant findings in all these
metabolic functions of CoQ and their relations with the pathomechanisms of some metabolic diseases,
highlighting some future perspectives and potential therapeutic implications.
Keywords: coenzyme Q10; ubiquinone-10; ubiquinol-10; mitochondria; OxPhos; super-complexes;
sulfide metabolism; one-carbon metabolism; proline metabolism
1. Introduction
Ubiquinone or coenzyme Q (CoQ) is an endogenously synthesized vital molecule that
is present in many unicellular and pluricellular organisms, the latter being mostly localized
in the mitochondria. In mammalian cells, at least 14 proteins are needed to synthetize
CoQ, and its biosynthesis starts with the formation of a 4-hydroxybenzoic acid (4-HB) head
group and a lipophilic polyisoprenoid tail. Whereas the 4-HB is derived from tyrosine or
phenylalanine, the polyisoprenoid tail is produced by addition of isopentenyl diphosphate
molecules, derived from the mevalonate pathway, to farnesyl diphosphate or geranyl-
geranyl diphosphate in multiple steps catalyzed by the polyprenil diphosphate synthase.
In human and mice, this enzyme is a heterotetramer and the two subunits are encoded
by PDSS1 and PDSS2. Another enzyme, encoded by COQ2, mediates the conjugation of
the benzoquinone ring to the side chain; while four others, encoded by COQ3, COQ5, COQ6
and COQ7, reside in the mitochondrial inner membrane and modify the benzoquinone
ring of CoQ by reactions of methylation, decarboxylation and hydroxylation [1]. Moreover,
four other proteins, encoded by COQ4, COQ8A, COQ8B and COQ9, seem to have differ-
ent regulatory functions over other CoQ biosynthetic proteins [1]. In particular, COQ9
physically interacts with COQ7 and has the ability to bind some CoQ biosynthetic interme-
diates, including demethoxyubiquinone (DMQ), the substrate for COQ7 [2,3]. Furthermore,
some other proteins (ADCK1, ADCK2, ADCK5 and PTC7p), may have the capacity to
increase/reduce the CoQ biosynthetic rate by phosphorylating/dephosphorylating some
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CoQ biosynthetic proteins, e.g., COQ7, or by other unknown mechanisms [1]. However,
the CoQ biosynthesis in mitochondria is not fully understood. Interestingly, Golgi has
the COQ2 homolog UBIAD1 [4], which also supports the biosynthesis of CoQ also in this
organelle.
Mutations in any of the genes involved in CoQ10 biosynthesis cause primary CoQ10
deficiency, a mitochondrial syndrome associated with clinically heterogeneous diseases.
Specifically, five major phenotypes have been described: (1) encephalomyopathy (recur-
rent myoglobinuria, encephalopathy and mitochondrial myopathy), (2) cerebellar ataxia
(cerebellar atrophy associated with other neurologic manifestations and, occasionally,
endocrine dysfunctions), (3) infantile multisystemic form, (4) isolated myopathy, character-
ized by muscle weakness, myoglobinuria, exercise intolerance and elevated creatine kinase
(CK), and (5) nephropathy. Hypertrophic cardiomyopathy, retinopathy or optic atrophy,
and sensorineural hearing loss have been also reported in some patients [5]. Addition-
ally, CoQ10 deficiency has been identified as a secondary consequence of other medical
conditions. This category includes patients with mutations in the aprataxin (APTX) gene,
causing ataxia and oculomotor apraxia, with mutations in the electron-transferring flavo-
protein dehydrogenase gene (ETFDH), causing isolated myopathy, and with mutations
in Serine/threonine-protein kinase B-raf (BRAF), causing cardiofaciocutaneous (CFC) syn-
drome [6]. Moreover, CoQ10 deficiency has been reported in association with pathogenic
mitochondrial DNA (mtDNA) depletion, deletions, or point mutations [6]. Also, a decrease
in the levels of CoQ biosynthetic proteins has been related to secondary CoQ deficiency
in various mouse models of mitochondrial diseases [7], as well as in muscle and adipose
tissue of patients and a mouse model with insulin resistance [8]. The wide clinical spectrum
of CoQ10 deficiencies must be related to its structure, characteristics and multiple metabolic
functions.
Structurally, CoQ is differentiated into a benzoquinone ring, which confers the redox
properties of the molecule, and a polyprenoid tail, which is responsible for its lipophilic-
ity [1,9,10]. The benzoquinone ring may exist in three redox states, fully oxidized (pro-
ducing ubiquinone), semiquinone radical (producing ubisemiquinone) and fully reduced
(producing ubiquinol). Also, the polyprenoid tail may be different in size, which is a char-
acteristic of the different CoQ forms present in different organisms. This size seems to be
determined by the homolog of the human PDSS1 protein in different species. For instance,
the polyprenoid tail of the CoQ in Saccharomyces cerevisiae has six isoprenoid units, leading
to the production of Coenzyme Q6 (CoQ6), mouse has a major form of nine isoprenoid
units and a minor form of ten isoprenoid units, leading to the production of Coenzyme Q9
(CoQ9) and Coenzyme Q10 (CoQ10) respectively, and in human, CoQ10 is the major form,
and CoQ9 is the minor one [1]. The distribution of CoQ9 and CoQ10 in mouse and human
varies between tissues and cell types, but specific functional differences between both CoQ
forms have not been described as yet [1].
The lipophilicity and the redox capability provide CoQ with the characteristics to
perform most of its functions. Generally, CoQ is considered as one of the most important
endogenous antioxidants, being especially effective in reducing/preventing lipid peroxida-
tion. This antioxidant role of CoQ has been confirmed by (1) studies of characterization
of in vitro and in vivo models of CoQ deficiency, which show increased generation of
reactive oxygen species (ROS) and oxidative damage, pointing out CoQ’s role in ROS gen-
eration and scavenging, (2) studies of CoQ10 supplementation in the same models of CoQ
deficiency, showing that the rescue of biochemical and clinical phenotypes and survival
correlate with improvement of oxidative stress, demonstrating the antioxidant effects of
CoQ10, and (3) studies in different models of increased oxidative stress in which CoQ10 is
able to reduce markers of oxidative damage [2,11–16]. The antioxidant capacity of CoQ is
due to its capability to directly reduce ROS, but also to regenerate other antioxidants, e.g.,
tocopherol and ascorbate [17]. To work as an antioxidant, CoQ must be able to reduce itself
after being oxidized. This can be done by different NAD(P)H oxidoreductases localized
in the plasma membrane, such as NADH-cytochrome b5 reductase, NAD(P)H:quinone
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oxidoreductase 1, or NADPH-CoQ reductase [17]. For all these functions in cell mem-
branes, CoQ must be distributed among them and that distribution seems to be regulated
by specific proteins [18,19].
In addition to this antioxidant capacity and redox regulation, which have been exten-
sively reviewed in the literature, CoQ has other key metabolic functions in mitochondria,
where its main biosynthetic process mostly occurs. Thus, this review is focused in de-
scribing the functional metabolic roles of CoQ in mitochondria and how, through those
functions, CoQ can also influence other metabolic pathways outside of mitochondria.
Particularly, this review provides an in-depth look at the metabolic pathways linked to
a functional structure called the CoQ-junction (Figure 1). As we will emphasize, all these
processes have important physiological and pathophysiological implications.
Figure 1. Metabolic uses of coenzyme Q (CoQ) in mitochondria. CHDH = choline dehydrogenase; ETFDH = electron
transfer flavoprotein dehydrogenase; SQOR = sulfide:quinone oxidoreductase; PRODH = proline dehydrogenase; GPD2 =
glycerol phosphate dehydrogenase; DHODH = dihydroorotate dehydrogenase. The above image represents the forward
electron transport and the image below, the reverse electron transport (RET).
2. CoQ in the OxPhos System
CoQ was first isolated by Professor Frederick Crane in 1957 in beef heart, describing
the presence and function of CoQ in the mitochondrial respiratory chain. Since then, its pro-
prieties as a mobile electron carrier in the mitochondrial respiratory chain and as a molecule
with redox capabilities in the cell have been widely studied [20]. In mitochondria, CoQ is
mainly localized in the inner mitochondrial membrane, where it accepts electrons from
NADH through NADH ubiquinone oxidoreductase (CI), and/or from FADH2 through suc-
cinate dehydrogenase (CII). Those electrons are then transferred to cytochrome c through
CoQH2-cytochrome c reductase (CIII), and the cytochrome c transfers the electrons to
the oxygen through cytochrome c oxidase (CIV). The transfer of electrons among the com-
plexes is accompanied by the pumping of protons to the intermembrane space, generating
a proton motive force that is used by the ATP synthase (CV) to produce the ATP. The trans-
fer of electrons in the mitochondrial respiratory complexes is favored by the formation of
super-complexes, a supramolecular organization that joins the mitochondrial individual
complexes in one single structure, in which CoQ is an essential component [21]. Therefore,
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the complexes can be found individually or, varying in the number of complexes, organized
in super-complexes, which encompass complexes I, III and IV. CII, however, has not been
proven to be in association with any other complex [22,23]. Both individual complexes
and super-complexes are functional, indicating that the organization in super-complexes
has to provide some advantages over the individual complexes, i.e., better stability, lower
ROS production, or a better mobilization of the electron transfer from the mobile carriers,
CoQ or cytochrome c, to their targets [21]. For years, CoQ was thought to be free in the mi-
tochondrial membranes in a homogeneous pool ready to be used by any enzyme that
needed it [24]. However, more recently, it has been demonstrated that the supramolecular
organization of complexes in super-complexes dynamically segments the CoQ molecules
in: (1) a pool attached and engulfed by the super-complexes I + III, exclusively dedicated to
the oxidation of NADH (CoQNADH pool), and (2) a free pool, available for CII or any other
enzyme that uses CoQ as a cofactor (CoQFADH pool) [25]. However, the two pools can inter-
act with each other. For example, fasting leads to an energy shift from glucose to fatty acids,
which results in a decrease in the NADH/FADH2 ratio. In that situation, the CoQFADH
pool can be over-reduced and the electron flux could be reversed in order to reduce NAD+
through the CoQNADH pool, thus restoring the oxidized CoQ [25]. This reverse electron
transport (RET) from CoQ to NAD+ enhances the scape of electrons and produces an accu-
mulation of ROS in the form of anion superoxide at the level of CI, resulting in CI-derived
oxidative damage [25,26]. The CI-derived oxidative damage leads to the degradation of CI
with the subsequent release of CIII and CoQNADH pool from the super-complexes. This par-
tial release of the CoQNADH pool is then used to restore the oversaturated CoQFADH pool
by the shift in the metabolism from carbohydrates to fats [25]. In addition, the generation
of the RET could be enhanced by the electrons that other enzymes transfer to CoQ, such as
glycerol-3-phosphate dehydrogenase or the electron-transferring flavoprotein, also leading
to ROS production [16,26]. Therefore, both the direction of the flow of electrons in the mi-
tochondrial respiration and the formation of mitochondrial complexes/super-complexes
are modulated by the CoQH2/CoQ ratio, which serves as a sensor to the metabolic status
of the mitochondria [27]. This key role of the CoQH2/CoQ ratio has been experimentally
demonstrated with the uses of the alternative oxidase (AOX), which accepts electrons from
CoQ and, therefore, contributes to decrease the CoQH2/CoQ ratio, resulting in a decline
of RET and ROS production [28]. However, it is important to highlight that the ROS
derived from RET may provide some beneficial effects since they can work as cellular
signalers. The toxic or beneficial effect of ROS depends on their amount, localization and
type of ROS [29]. In fact, ROS production via RET at CI, controlled by the CoQH2/CoQ
ratio, has been associated with different physiological processes, such as: (1) the in vitro
differentiation of myoblasts into myotubes [30], (2) the metabolic shift from carbohydrates
to fatty acids [27], (3) the macrophages’ reprograming and activation under bacterial stim-
uli [31], (4) the sensing of oxygen levels by the specialized cells in the carotid body [32], (5)
the increase of the lifespan in Drosophila melanogaster [33] or (6) in the oxidative damage
produced by the reperfusion of heart or brain after infarction or stroke, since the interrup-
tion of electron flow induces the accumulation of succinate in the ischemic phase of these
conditions, follow by a rapid use of that succinate in the reperfusion phase, leading to
an increase of the CoQH2/CoQ ratio and RET [34,35]. This underlies the importance of
the CoQH2/CoQ ratio and RET in both physiological and pathophysiological contexts.
From a different perspective, the importance of CoQ in the mitochondrial respiratory
chain is evidenced by the OxPhos defect and decreased ATP production in tissues from
patients with primary CoQ10 deficiency, as well as in cells and animal models of CoQ
deficiency [5]. For instance, decreased activities of CoQ-dependent mitochondrial com-
plexes have been described in muscle and/or skin fibroblasts from the first patients with
identified molecular defects in the CoQ biosynthetic pathway, i.e., COQ2, PDSS2, PDSS1 or
COQ9 [36–40]. Curiously, the severity of the OxPhos defect inversely correlates with ROS
production and oxidative damage in skin fibroblasts from patients with primary CoQ10
deficiency [12,13]. This correlates with the low mitochondrial ROS production in the car-
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diac mitochondria from the Coq7 conditional Knockout (KO) mice, which contains only
10% of the normal CoQ levels [41]. The connection between CoQ levels and bioenergetics
defects has also been demonstrated in conditions of pharmacological inhibition of CoQ
biosynthesis in human skin fibroblasts and neurons [15]. Also, mouse embryonic fibroblasts
(MEFs) from a Coq7 knockout mouse model or a Coq9 knock-in mouse model (Coq9R239X),
generated by independent groups, show a reduction in mitochondrial respiration and a de-
crease in ATP production [42–45]. COQ7 is a hydroxylase that uses demethoxyubiquinone
(DMQ) as substrate in the CoQ biosynthetic pathway, and it needs COQ9 for its stability
and function [2,3,44]. Consequently, Coq7 knockout mice and Coq9R239X mice accumulate
DMQ, which could compete with CoQ and inhibit the CI + III activity [46]. Additionally,
the mouse model of CoQ deficiency due to a spontaneous mutation in Pdss2 (Pdss2kd/kd)
shows decreased activities of complex I and II + III activities in kidneys, the most clinically
affected tissue [47]. Interestingly, OxPhos defects in cell and animal models of CoQ defi-
ciency are not always rescued by CoQ10 supplementation, and their role in the pathogenesis
of the disease seems to be variable, probably depending on the molecular defect and/or
tissue specificity. In vitro, CoQ10 supplementation for 7 days normalizes the ATP levels
and ATP/ADP ratio in skin fibroblast from patients with mutations in PDSS2, COQ2 and
COQ9 [48]. However, other short-tail ubiquinone analogs are not able to restore the ATP
synthesis, demonstrating the importance of the CoQ structure in the function of the OxPhos
system [48]. In vivo, the low absorption and bioavailability of the exogenous CoQ10 limits
its bioenergetic effects in some tissues. In Pdss2kd/kd mice, CoQ10 supplementation does
not rescue the CoQ-dependent complexes activities in kidneys, although therapeutic bene-
fits were reported, presumably due to other CoQ10 functions [47,49]. In Coq9R239X mice,
ubiquinol-10 (CoQ10H2), but not ubiquinone-10 (CoQ10), is able to partially increase CI +
III activity in the brain due to its superior absorption, bioavailability and mitochondrial
uptake [50], leading to an increase in survival [51]. Since Coq9R239X mice accumulates DMQ,
the reduction in the levels of DMQ achieved by the treatment with beta-resorcylic acid
(β-RA) is able to increase the bioenergetics and obtain therapeutic outcomes that are supe-
rior to those obtained under CoQ10H2 supplementation [51]. The decrease on the levels of
DMQ, and its subsequent therapeutic benefits, is also achieved by b-RA in the conditional
knockout Coq7 mouse model, as well as in skin fibroblasts from patients with mutations
in COQ7 or COQ9 [41,52,53], pointing out the structural specificity of CoQ in its function
in the mitochondrial respiratory chain. The importance of CoQ in the OxPhos system
has also been revealed in cases of secondary CoQ deficiencies, although, in those cases,
it is unclear the contribution of the different functions of CoQ to the pathophysiologic
characteristics of the disease.
3. The Role of CoQ in the Regulation of Sulfide Metabolism and Others Linked
Pathways
Given its central role in the mitochondrial respiratory chain, CoQ links the mitochon-
drial respiratory chain to other mitochondrial enzymes and pathways in the functional
structure called the CoQ-junction. One of these enzymes is the sulfide:quinone oxidore-
ductase (SQOR), which catalyzes the first step in the mitochondrial sulfide oxidation
pathway. SQOR couples H2S oxidation to CoQ reduction, forming a protein-bound per-
sulfide (Figure 2). The SQOR-bound persulfide is transferred to a sulfane sulfur acceptor,
e.g., such as glutathione (GSH) or sulfite, resulting in the generation of GSH persulfide
(GSSH) or thiosulfate, respectively. The persulfide group from GSSH is further oxidized
to sulfite by an iron-dependent sulfur dioxygenase (SDO) (also known as ETHE1 or per-
sulfide dioxygenase). Sulfite can then either be oxidized to sulfate by sulfite oxidase
(SO) or converted to thiosulfate via addition of a persulfide catalyzed by the thiosulfate
sulfurtransferase or rhodanese (TST). The sulfane sulfur from thiosulfate can be remo-
bilized by another sulfurtransferase called thiosulfate reductase (TR) (Figure 2) [54–57].
The H2S used as a substrate by the SQOR is produced by at least three enzymes, of which
two are in the transsulfuration pathway (Figure 2), localized in the cytosol. These two
enzymes are Cystathionine β-synthase (CBS), which produces H2S primarily by conden-
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sation of cysteine and homocysteine, and cystathionine γ-lyase (CSE), which produces
H2S primarily by α- and β-elimination of cysteine, generating pyruvate and ammonia.
A third enzyme, 3-mercaptopyruvate sulfurtransferase (3MST) [56], produces H2S from
3-mercaptopyruvate (3MP), an achiral α-keto acid generated by cysteine aminotransferase
(CAT) from L-cysteine and α-ketoglutarate (α-KG). The CAT/3MST pathway has also been
detected in mitochondria, which opens the possibility of an intramitochondrial production
of H2S (Figure 2) [58].
Figure 2. The biosynthetic (transsulfuration) and catabolic (oxidation) pathways of H2S. Transsulfu-
ration pathway involves the enzymes cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE)
and pyridoxal-5′-phosphate (PLP)-independent 3-mercaptopyruvate sulfurtransferase (3MST). Mi-
tochondrial H2S oxidation pathway involves the enzymes sulfide:quinone oxidoreductase (SQOR),
sulfur dioxygenase (SDO; also known as ETHE1 or persulfide dioxygenase), sulfite oxidase (SO),
thiosulfate sulfurtransferase or rhodanese (TST) and thiosulfate reductase (TR).
The regulation of production and the use of H2S occurs at the level of expression
and activity of the biosynthetic and catabolic enzymes. For example, tonic inhibition of
CBS is relieved during hypoxia, leading to elevated H2S production [59], the restriction
in sulfur aminoacids (SAAs) upregulates the transsulfuration pathway, increasing H2S
production [60,61], or the levels of SQOR are increased under hypoxia and restriction
in SAAs [62,63]. However, an integration of regulatory aspects in both the biogenesis
and the catabolism of H2S has not been clearly formulated. Recently, our group has
demonstrated that CoQ10 supplementation leads to an upregulation of SQOR, together
with a downregulation of CBS and CSE, in vitro (Figure 3) [64].
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Figure 3. The relation of CoQ with sulfide metabolism and other linked pathways. The upper panel shows how CoQ is
connected to sulfide metabolism and one-carbon metabolism. The bottom panel shows the main finding on these pathways
in conditions of supraphysiological levels of CoQ10 or deficiency in CoQ10. SQOR = sulfide:quinone oxidoreductase; CBS =
cystathionine-β-synthase; CSE = cystathionine γ-lyase; GSH = glutathione; H2S = hydrogen sulfide; GPx4 = glutathione
peroxidase 4.
Therefore, CoQ10 regulates both pathways in opposite directions by modifying the gene
expression and protein levels of SQOR, CBS and CSE. Although the mechanisms of this
regulation have not been identified yet, these results may have relevant therapeutic impli-
cations for diseases with disrupted H2S metabolism. For instance, the reduction in the H2S
levels, as a consequence of the effects of CoQ10 supplementation, could be a therapeutic
approach in genetic diseases with defects in sulfide metabolism enzymes, i.e., the ethyl-
malonic encephalopathy caused by mutations in ETHE1 [65], or the Leigh syndrome
caused by mutations in SQOR [66]. In both cases, the accumulation of high levels of H2S
induces mitochondrial toxicity and, consequently, the repression of the CBS and CSE,
together with the stimulation of SQOR, may limit that toxicity by reducing the levels
of H2S. CoQ10 supplementation may also provide therapeutic benefits in more common
diseases, where cell-specific accumulation of H2S has been reported. For example, a de-
crease in the enzymes involved in the H2S oxidation pathway has been reported in the gut
of mouse models and patients with Crohn’s Disease, together with a relative increase
in the abundance of H2S microbial producers, resulting in pathological accumulation of
H2S that contributes to the disease [67], and the increase in CBS has been reported in human
biopsies of precancerous adenomatous polyps [68].
The transsulfuration pathway, and specifically, mRNA levels, protein levels and ac-
tivities of CSE or CBS, has been linked to alterations in other metabolic pathways, such
as serine and nucleotides biosynthesis or folate cycle [7,69,70]. Several evidences have
demonstrated the contribution of these alterations to pathophysiological states related
to mitochondrial dysfunction, such as: (1) the inhibition of CI in human cells causes
an upregulation of the mRNA levels of CBS and CSE, together with the upregulation of
PSAT1, SHMT2 and PHGDH, which are involved in serine/glycine biosynthesis and folate
cycle [71], (2) the levels of the MTHF2 protein, involved in the folate cycle, are increased
in the Deletor mouse model, a mouse model with accumulation of mtDNA deletions,
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resulting in modifications in one-carbon metabolism [72], (3) the levels of MTHF2 and
SHTM2 proteins are increased in other mouse models of mitochondrial diseases caused
by defects in mtDNA [7], (4) CBS, CSE, PHGDGH, PSPH and PSAT1 mRNAs are upreg-
ulated in other human cell models of pharmacologically induced mtDNA depletion [73]
and (5) MTHFD1L, MTHFD2, PSAT1 and PHGDH are upregulated in patients with mi-
tochondrial myopathy caused by mtDNA deletion [70]. Thus, the regulatory effects of
CoQ over sulfide metabolism could indirectly modulate these pathways and, consequently,
provide therapeutic benefits on these pathophysiological states (Figure 3). In fact, the ser-
ine/glycine ratio is increased by the supplementation with CoQ10 in vitro, together with
a metabolic adaptation of nucleotides biosynthesis and folate cycle [64]. Therefore, CoQ10
supplementation could be beneficial in pathologies with alterations in sulfide metabolism,
serine biosynthesis, folate cycle or nucleotide metabolism by repressing CBS, CSE, PHGDH,
PSAT1 and MTHDF1L, among others [64].
The role of CoQ in sulfide metabolism and related pathways has also been demon-
strated in models of primary CoQ deficiency. Two independent studies showed that either
in vitro, in skin fibroblasts from patients with primary CoQ10 deficiency, or in vivo, in two
different mouse models of primary CoQ deficiency, the deficiency in CoQ leads to reduced
activity and levels of SQOR [74,75]. The consequence of this reduction is an increase
in the amount of H2S and a reduction in the levels of glutathione (GSH), an antioxidant
composed by glutamate, cysteine and glycine, the last two linked to H2S metabolism [74,75].
In one study, two mouse models of CoQ deficiency caused by different mutations in Coq9
were used [75]. The Coq9Q95X mouse model, which has a mild reduction of CoQ levels
and shows mild signs of late-onset myopathy, has reduced levels and activity of SQOR
in the skeletal muscle. The Coq9R239X mouse model, which has a severe reduction in CoQ
levels and suffers a fatal mitochondrial encephalopathy, has severe reduction in the levels
and activity of SQOR in the brain, kidneys and skeletal muscle [75], and, as a consequence,
the CBS levels are increased [64]. Besides, the levels of SQOR downstream enzymes, Sul-
fite Oxidase (SO) and Thiosulfate Sulfurtransferase (TST), but not ETHE1, are increased,
most likely as a compensatory mechanism [75]. Moreover, the most clinically affected
tissue in Coq9R239X mice, the brain, shows a reduction in the levels of total GSH, together
with a decrease in the levels and activities of the glutathione reductase (GRd) and glu-
tathione peroxidase 4 (GPx4) enzymes [75]. Interestingly, CoQ and GPx4, together with
the apoptosis-inducing factor mitochondria-associated 2 (AIFM2), have been related to
the suppression of ferroptosis, a cellular process that has not been evaluated in CoQ defi-
ciency [76,77]. Furthermore, the levels of specific metabolites of the serotonin biosynthesis
pathway and the levels of tyrosine are increased. This may suggest that sulfide metabolism
can interact and alter the neurotransmitter biosynthesis. Accordingly, similar alterations
in the levels of L-glutamate, dopamine and 5-hydroxyindoleacetic acid are detected in wild-
type animals treated with H2S donors [75]. Furthermore, the effects of H2S, a well-known
vasodilator [78], cause low blood pressure in Coq9R239X mice. These abnormalities are
rescued by the treatment with b-RA [51], which, as previously mentioned, rescues CoQ
deficiency due to mutations in Coq7 or Coq9 [41,51–53].
Another study used the Pdss2kd/kd mice, which suffer from nephrotic syndrome [74].
Pdss2kd/kd mice show severe reduction in the levels of SQOR in the kidneys. In this model,
however, contrary to what was observed in Coq9 mutant mice and human CoQ-deficient
fibroblasts, also, SQOR downstream enzymes TST, SO and ETHE1 are downregulated,
indicating genotype- and/or tissue-specific mechanisms. As a consequence, H2S levels
are increased, and GSH levels are decreased in the kidneys of Pdss2 mice [74]. Moreover,
urine and plasma thiosulfates are decreased, and short-chain acylcarnitine is increased
in plasma of these mice. The altered acylcarnitine profile might result from inhibition
of short-chain Acyl-CoA dehydrogenase (SCAD) by H2S, or might be the consequence
of low levels of CoQ on lipid metabolism, as discussed in the next section of this review.
In any case, chronic administration of oral CoQ10 increases SQOR and the other enzymes
of the H2S oxidation, and GSH levels, normalizes plasma acylcarnitine profile and prevents
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renal failure in Pdss2kd/kd mice [48]. Therefore, the disruption in sulfide metabolism is
one of the pathomechanisms of primary CoQ deficiency and it should be considered for
the development of new treatments [47,51,74,75].
4. Other CoQ-Linked Reactions in Mitochondria
CoQ receives electrons from other enzymes of different metabolic pathways in the CoQ-
junction (Figure 1). It receives electrons from dihydroorotate dehydrogenase (DHODH),
which catalyzes the conversion of dihydroorotate to orotate, the fourth reaction step within
pyrimidine de novo biosynthesis [79]. Therefore, the pyrimidine de novo biosynthesis
is directly connected to CoQ and, consequently, low levels of CoQ may impair uridine-
5′-triphosphate (UTP), cytidine 5′-triphosphate (CTP) and deoxythymidine triphosphate
(dTMP) synthesis, as well as RNA and DNA synthesis. In fact, supplementation with
uridine, the precursor of UTP, CTP and dTMP in the pyrimidine salvage pathway [80],
increases the growth rate in CoQ10-deficient fibroblasts, but not in wild-type fibroblasts [36].
Moreover, secondary CoQ10 deficiency has been reported in patients with mitochondrial
DNA depletion due to mutations in DGUOK (encoding mitochondrial deoxyguanosine
kinase, which is involved in the purine nucleotide salvage pathway), SUCLA2 (encoding
the β subunit of succinyl-CoA synthase, which is involved in the Krebs cycle), MPV17
(involved in mitochondrial deoxynucleoside triphosphates pool homeostasis) or from
unknown etiology [81,82]. The CoQ-dependent DHODH seems to also be important in tu-
morigenesis since the pyrimidine biosynthesis required in mouse breast cancer cells need
a functional CoQ redox-cycling and DHODH activity [83].
CoQ also receives electrons from the electron transfer flavoprotein-dehydrogenase
(ETFDH), which serves as a short electron transfer pathway to conduct electrons from nine
different mitochondrial flavin adenine dinucleotide (FAD)-containing acyl-CoA dehydro-
genases of fatty acid β-oxidation and amino acid catabolism to the ubiquinone pool [84].
Curiously, some patients with mitochondrial myopathy due to mutations in ETFDH show
CoQ10 deficiency, although the precise mechanisms for this association are unknown [85,86].
Importantly, a trend toward decreased levels of short- and medium-length acylcarnitines
are showed in the liver and kidneys of Pdss2kd/kd, while the levels of acylcarnitines C4, C5
and C6 are increased in plasma of the same mice, indicating a defective oxidation of fatty
acids [74].
A third type of enzymes that use CoQ as electron acceptors are proline dehydroge-
nase and proline dehydrogenase 2 (PRODH and PRODH2) [87,88], which are related with
proline, glyoxylate and arginine metabolism. Interestingly, PRODH2 has been proposed
as a molecular target for treating primary hyperoxaluria, and some CoQ analogs seem
to stimulate PRODH2 activity [87]. The remaining mitochondrial enzymes that use CoQ
are glycerol 3-phosphate dehydrogenase (GPD2) [89], which connects glycolysis, OxPhos
and fatty acids metabolism, and choline dehydrogenase (CHDH) [90], which is involved
in the glycine metabolism. Remarkably, the behavior of these CoQ-linked proteins in CoQ
deficiency seems to be different from SQOR, since kidneys of Coq9R239X mice show an in-
crease in the levels of ETFDH, CHDH, DHODH, PRODH and PRODH2 [3] (Table 1), most
likely due to a compensatory mechanism, although the functional evaluation of theses
enzymes has not been assessed in CoQ deficiency.
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Table 1. Levels of the CoQ-linked proteins in Coq9R239X mice compared to Coq9+/+ mice. The values





GPD2 −0.0407 0.2659 0.0454
ETFDH 0.1131 −0.1072 0.0665
CHDH 0.1572
DHODH 0.2237
PRODH 0.4076 0.1372 0.5226
PRODH2 0.6400
The results were obtained by liquid chromatography (LC) - Mass spectrometry (MS)/MS using tandem mass
tagging to measure relative protein abundances [3].
Other mitochondrial components susceptible to be regulated by redox reactions are
the UCPs. Controversial results have been reported on the involvement of CoQ in the regu-
lation of the UCPs. By using bacterial overexpressed UCP1, 2 and 3 in liposomes, Echtay
and colleagues [91,92] showed that CoQ, but not CoQH2, activated the H+ transport
through the UCPs. These studies suggested that CoQ acts as a non-covalent UCP cofac-
tor in cooperation with other well-known UCPs modulators, such as free fatty acids or
retinoids. Later on, Jaburek and Garlid [93] optimized the conditions of isolation and
refolding of bacterially expressed UCPs and evaluated the effect of CoQ in the same model.
Contrary to what was reported by Echtay and colleagues [91,92], they found that CoQ had
no effect on the proton transport catalyzed by any of the UCPs [93]. Similar conclusions
were documented by Esteves and collaborators using a CoQ-deficient yeast model [94].
Nevertheless, a more recent study showed that CoQ, through its redox state, is a regulator of
the inhibition, by purine nucleotides, of free fatty acid-activated UCP1 homologues under
phosphorylating respiration conditions [95]. Therefore, additional studies are required to
elucidate the role of CoQ in the modulation of UCPs activities, especially under physiologi-
cal conditions and taking into account potential type- and tissue-specific differences. Also,
some reports have shown that CoQ10, as well as other short-tail CoQ analogs, can function
as modulators of apoptosis by the regulation of the mitochondrial permeability transition
pore (PTP) [96–98]. As it happens with other CoQ functions, the size of the polyprenoid
tail has functional implications, i.e., CoQ10 inhibits PTP opening induced by H2O2, CoQ5
does not produce any effect on the PTP opening induced by H2O2, while CoQ0 induces
PTP opening and H2O2 production [99]. However, cell- and tissue-specific differences
have been observed [99,100], and, consequently, additional studies in physiological and
pathophysiological conditions are required to better understand the role of CoQ10 and
other short-tail analogs in the regulation of the mitochondrial PTP opening.
5. Conclusions and Perspectives
From the first isolation of CoQ, its role in the mitochondrial respiratory chain and
energy production has been clearly demonstrated. The generation and characterization
of different models of CoQ deficiency and studies of CoQ10 supplementation in the same
models have confirmed it. Also, recent studies have unveiled the importance of the redox
state of CoQ in the regulation of super-complexes’ formation and, consequently, in the use
of the reducing equivalents by the respiratory chain, as well as in the production of ROS.
These data could open the possibility to modulate/modify the energy metabolism through
physiological or pharmacological interventions that target the redox state of CoQ. Besides
its implication in the mitochondria respiratory chain, CoQ is also a key component in the re-
actions mediated by other mitochondrial enzymes and, therefore, CoQ links the energy
production to other metabolic pathways of the cell. The contribution of these CoQ-linked
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enzymes to RET must be better defined in different physiological and pathophysiological
conditions. Also, whether all these metabolic pathways related to the CoQ-linked enzymes
are influenced by CoQ levels, including the cases of primary and secondary CoQ deficien-
cies, or CoQ redox state, remains to be evaluated. However, recent studies indicate that
modifying the levels of CoQ and/or its redox state indeed affects some of these pathways,
i.e., sulfide metabolism, in the mitochondrial and cytosolic compartments. In any case,
the link between CoQ, sulfide metabolism, one-carbon metabolism, glutathione and fer-
roptosis shown in recent studies must be validated and further investigated in different
models. Furthermore, those pathways could be influenced by an alteration in the distribu-
tion of CoQ among the different compartments of the cell. However, our knowledge about
the mechanisms of CoQ distribution in the cell is still very limited, and it is unknown if
the cell responds with a redistribution in the CoQ pool under CoQ deficiency. Together,
the results exposed above prove the relevance of CoQ10 beyond its classical function as
an electron carrier in the mitochondrial respiratory chain and, consequently, they may have
significant implications in the use of CoQ10 supplementation in patients with different
metabolic diseases. Nevertheless, additional research studies are required in models of CoQ
deficiency, models of CoQ10 supplementation and models with different redox states of
CoQ, paying close attention to the bioavailability of the exogenous CoQ10 and the potential
cell- and tissue-specific differences.
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